These recent reports suggest that newer arsenals are beginning to emerge for AR-targeted therapeutics which could be useful in improving the therapeutic outcome of PCa patients especially for patients with CRPC and/or mCRPC. This evidence concerns the gene AR and posterior cortical atrophy.